text:
Please enter a valid mileage
Curious about the newer model? Check out the 2015 Honda Civic
By KBB.com Editors
As Honda's best-known and best-loved car line, the 2008 Civic Sedan and Coupe continue to set the bar in the compact-car arena. Long considered the standard by which all other compacts are measured, the Civic is able to lure buyers thanks to its impressive fuel economy, unrivaled reliability and repair history and class-leading resale values. Once considered the Civic's only weak point, exterior styling is now one of the car's most appealing attributes. With its sharply raked windshield and low profile, the sleek Civic Coupe looks like nothing else on the road. The car's appeal to younger drivers has put Honda back into the good graces of the tuner and aftermarket crowd.
If you appreciate world-class refinement (along with impressive mileage), and you're looking to spend anywhere from $15,000 to $23,000 for a new car, your test-drive schedule might not continue past the Honda dealer.
If the Civic's $15,000 starting price is the most you want to spend, you might be disappointed to find out the base model doesn't offer a factory-installed audio system, air conditioning, power locks, center console or even map lights.
The Civic EX-L Sedan and Coupe introduce leather seating to the Civic line, while the Mugen Si Sedan debuts with a performance suspension, forged aluminum wheels and a sport tuned exhaust.
Driving Impressions We drove the Civic in both coupe and sedan form and found them both notable for what you don't hear or feel---the ride is smooth and quiet, while cornering and...acceleration are easy and nearly effortless. The whole experience is more in line with what you'd expect from a bigger or pricier vehicle. The refined 140-horsepower engine never overwhelms you with power, but even when you run the tachometer up to its redline you don't feel like you're bullying the car. The coupe version gets a slightly sportier suspension to go with its decidedly sportier posture, but we found it to be still comfortable after hour-plus drives. Whether you're in the driver's seat or one of the Civic's other seating positions, the 2008 Honda Civic is a perfectly enjoyable way to travel.
Audio Options
Listen to MP3s on CD. Listen to MP3s on a memory card. Listen to MP3s on an iPod. Listen to XM Satellite Radio. Listen through a 350-watt system with a subwoofer (coupe only). When you're feeling nostalgic, you can even listen to AM and FM radio broadcasts.
Two-Tier Instrument Panel
While some non-traditional instrument panel layouts come across as gimmicky, the Civic's two-tier execution seems to make all the sense in the world.
In addition to offering more in-cabin technology than we've come to expect, the 2008 Honda Civic also features the most visually futuristic interior of any vehicle on the market. Take a seat behind the wheel and your first impression is dominated by a uniquely sculpted steering wheel and an unconventional two-tier instrument panel. Technological highlights include an available navigation system and a broad array of digital audio options. Third, fourth and fifth passengers would be happier in the sedan's backseat than in the coupe's, because the sedan features about four more inches of legroom and two more inches of headroom than the cozy coupe. The fit, finish and design found inside the Civic are first-rate.Exterior
Although the 2008 Honda Civic Coupe and Sedan are both distinguished by a low-profile front end, short hood and long, laid-back windshield, the two models have never been more different. The taller sedan rides on a longer wheelbase than the sleeker, sportier coupe that also includes a decklid spoiler as standard equipment. Smaller gaps between the tires and body contribute to each model having a stance with better proportions and more balance. Beneath the sheet metal, the Civic features an advanced body structure designed to better absorb and distribute collision forces, especially in impacts involving taller sport utility vehicles and the like.
Notable standard equipment on the base Civic Sedan and Coupe models includes power windows, a four-way adjustable steering column, height-adjustable driver's seat, fold-down rear seatback and an impressive list of safety equipment such as front, front-side and side-curtain airbags, active head restraints, anti-lock brakes (ABS) and more. Notable as not included on the base DX trim level are an audio system, air conditioning and power locks/mirrors.
The Civic's list of optional equipment is highlighted by a navigation system with voice-recognition software. An advanced 350-watt AM/FM/XM/CD sound system with subwoofer is available on the Si Sedan and EX, EX-L and Si Coupe, but there are several iterations of a 160-watt CD sound system---and all audio systems have MP3/WMA CD playback capability. In addition to an auxiliary input jack for MP3 players, Honda offers an accessory adapter that lets you control an Apple iPod through the car's audio controls. Getting the navigation system also gives you the ability to play music stored on a variety of digital media cards. More familiar options are included within the various trim levels and include an automatic transmission, one-touch power moonroof, power door locks with keyless remote, power mirrors, air conditioning, cruise control and steering wheel-mounted cruise/audio/navigation controls.
Bridging the gap between the 197-horsepower high-output engine in the Civic Si and the 45-miles per gallon powerplant in the Civic Hybrid, the Civic sedan and coupe feature a 140-horsepower unit that delivers impressive city/highway mileage of up to 25/36-miles per gallon. A five-speed manual is standard, but a five-speed automatic mitigates the performance penalty normally associated with combining a small four-cylinder engine and an automatic transmission. Performance fans who can't work a manual gearbox are shut out of the Si, as no automatic is offered.
1.8-liter in-line 4
140 horsepower @ 6300 rpm
128 lb.-ft. of torque @ 4300 rpm
EPA city/highway fuel economy: 26/34 (manual), 25/36 (automatic)
2.0-liter in-line 4
197 horsepower @ 7800 rpm
139 lb.-ft. of torque @ 6100 rpm
EPA city/highway fuel economy: 21/29
To compare current market prices, check out KBB.com's car classifieds to view the new and used Honda Civic vehicles for sale near you.
Based on 1838 Ratings for the 2006 - 2011 models.Review this car
By First Time Buyer on Tuesday, March 31, 2015
I own this car - My approximate mileage is 75,000overall rating 2 of 10rating details
Pros: "Looked good."
Cons: "Only averaged 32 MPG."
Likely to recommend this car? (1-10): 1
"I had heard such great things about Honda. Unfortunately, this car did not live up to its reputation. The car was supposed to get between 48-50 MPG. My Honda, after almost 5 years, has averaged 32 MPG, which would not be bad if I hadn't paid an additional $2,000 for a hybrid. There was a class action suit against Honda because of this car. The only good thing I can say about this car is that it looked good when I bought it."
Was this review helpful to you? yes | no | report abuse
By Granny on Monday, March 30, 2015
I own this car - My approximate mileage is 29,000overall rating 2 of 10rating details
Pros: "Hybrid!"
Cons: "An unreliable lemon w/irreparable I battery issues"
Likely to recommend this car? (1-10): 1
"Three years of constant issues with the hybrid because of the battery problems! Finding out this was a known problem with the 2009 Civic Hybrid didn't change the frequent times I had to be towed or jumped. Dealer told me it was the battery. Replaced it. Still had problems. Dealer said it was the remote starter. Took it out. Still no fix. Second time they suggested I change the (new) battery, I gave up. Went back to dealer and gave them all the paperwork and took a loaner. Got home and found an apology letter from Honda admitting a problem and offering to pay for replaced batteries. Very frustrating since I drove a regular Civic previous to this hybrid and had no issues after 17 years. Dealership swears they won't put this car on the lot. Buyers, beware!"
Was this review helpful to you? yes | no | report abuse
By Jean on Friday, March 27, 2015
I own this car - My approximate mileage is 102,000overall rating 10 of 10rating details
Pros: "Reliable, comforatable, good pick-up."
Cons: "None except sun visor defect."
Likely to recommend this car? (1-10): 10
"Bought this car in 2012 when it was four years old. Had to have the sun visors replaced twice as there was a defect but dealer paid for this. The battery died about two years ago and I had that replaced and then the air went out summer of 2014 but it did not cost much to repair it. Other than, that it as been just typical oil and filter changes. Overall, a great car. The new Civics are much nicer and bigger than the really old Civics."
1 person out of 1 found this review helpful
Was this review helpful to you? yes | no | report abuse
By mike on Friday, March 20, 2015
I own this car - My approximate mileage is 71,000overall rating 10 of 10rating details
Pros: "excellent vehicle"
Cons: "has all a vehicle would need"
Likely to recommend this car? (1-10): 10
"Bought new has been serviced every 3000 miles with synthetic oil and filter trans oil changed every 6000 miles with honda synthetic fluid 3 quarts every 6000 miles holds six quarts. minor hood chips. car has tinted windows new micheline tires 60000 mile rating"
3 people out of 4 found this review helpful
Was this review helpful to you? yes | no | report abuse
By aburt138 on Tuesday, March 17, 2015
I own this car - My approximate mileage is 180,000overall rating 10 of 10rating details
Pros: "cost of ownership, mpg, maintanance"
Cons: "Road noise, low ground clearance"
Likely to recommend this car? (1-10): 10
"I've never had such an easy car you just oil it gas it and go. It got me through 2 college degrees, a marriage, new job, and new baby. I decided to get an suv since we are growing a family and mostly due to my husband wanted to get me a bigger vehicle. Otherwise, the 9 year old car runs fine. I replaced an alternator and starter but nothing else. Took me 30 minutes to pick this car out and buy it. I got in and immediately said this car is so comfortable. Roomy back seat and just fun to drive. I think it's still got a whole lot of life left even after 200k miles."
Was this review helpful to you? yes | no | report abuse
By Jack on Tuesday, March 17, 2015
I own this car - My approximate mileage is 73,000overall rating 9 of 10rating details
Pros: "See above"
Cons: "See above"
Likely to recommend this car? (1-10): 9
"My 2006 Civic Navi has been trouble-free over nine & a half years & 73,000 miles. For a completely new model (when I purchased the car), my car had no design or functional flaws. The only downside has been that the mileage (29+ m. p. g. over all the years) has been a bit less than I had hoped."
1 person out of 1 found this review helpful
Was this review helpful to you? yes | no | report abuse


text:
Wednesday, April 1, 2015 at 3:16pm
BECKLEY'S EAST COAST EXCURSION: After closing the Los Angeles boutique bearing her last name in January and another in Las Vegas two years earlier, Melissa Beckley is back in the retail business. The retailer-turned-designer plans to unveil a pop-up shop at 85 Mercer St. in New... read more
Wednesday, April 1, 2015 at 3:14pm
KANYE AND DAMON, GET IN LINE: Kanye West and Damon Dash are going to have to follow procedure if they want to buy bankrupt etailer Karmaloop, as they say they do. Senior lender Comvest Capital in the site's bankruptcy has been selected as the stalking horse to spur a bidding... read more
Wednesday, April 1, 2015 at 3:08pm
Happy feet: Laid-back Los Angeles label Wren has announced a collaborative capsule collection with espadrille brand Soludos for summer. The collection's three styles — an original slip-on design, as well as platform and sandal variations — are fabricated from handmade batik... read more
Wednesday, April 1, 2015 at 3:06pm
"Chanel!" Pharrell Williams said. "I can't believe I'm here right now. This is Chanel." Yes, it was so hard to believe Karl Lagerfeld staged a Chanel show in the middle of New York's Upper East Side Tuesday night, even Pharrell was incredulous. He was speaking from a makeshift... read more
Wednesday, April 1, 2015 at 2:00pm
Watch Action Bronson & Chef Michael White Make 'Mr. Wonderful'-Inspired Coastal Italian Food
No stranger to the fusion of hip-hop and culinary delights when it comes to his work, Action Bronson has chosen a more literal approach to doing press for his album, Mr. Wonderful, by having world-renowned chefs cook up dishes inspired by his music. While Mario Batali opted... read more
Wednesday, April 1, 2015 at 1:20pm
NYC's Unyforme unveils its latest set of spring apparel. A sporty selection of contemporary streetwear garb is presented in a minimal palette, with heathered gear executed in technical fabrics sitting alongside color-blocked sweats, vented tees and slim-fitting cuffed chinos.... read more
Wednesday, April 1, 2015 at 12:56pm
Sophie Rochas was a daddy's girl, but her father, designer Marcel Rochas, unfortunately died suddenly of an aneurysm when he was 53 and she was 10. Her relationship with her mother, La belle Hélène, was much shakier, and Hélène sued to block the publication of her daughter's... read more
Wednesday, April 1, 2015 at 12:40pm
Following an initial glimpse in early February, a second trailer for the F. Gary Gray-directed biopic about N.W.A., Straight Outta Compton, is now available. With the full cooperation of the various rapper's estates, the film hones in on the 5 individuals from Compton, CA who... read more
Wednesday, April 1, 2015 at 12:30pm
Amazon's newly launched Dash Button aims to alleviate the issue of running out of cleaning and other household products. Currently exclusive to Amazon Prime members, Dash Button comes with a reusable adhesive and a hook so you can hang, stick, or place it right where you need... read more
Wednesday, April 1, 2015 at 12:12pm
MILAN — With two weeks to go before design fair Salone del Mobile here, a joint Fondazione Altagamma and Bain study found that the design market worldwide had revenues of 90 billion euros, or $119.7 billion at average exchange, last year. Including unbranded products, the... read more

subset: commoncrawl


text:
Author Archive
Sun's Out, Grass is Out at Miller Park
Back in Milwaukee, unseasonably warm weather has everyone–including the grass–thinking spring.
This morning, the Michael Boettcher, Director of Grounds, and the Grounds Crew staff started pulling covers from the field at Miller Park:
Just another sign that we're #OneDayCloser to Opening Day–28 days and counting!
Bob Uecker Receives Vince Lombardi Award of Excellence
Tonight, Bob Uecker was honored at the Vince Lombardi Award of Excellence Dinner Ball, held at the Pfister Hotel in downtown Milwaukee.
Created in 1990, the Vince Lombardi Award of Excellence Dinner Ball was created as a means of recognizing individuals who have made a Hall of Fame contribution to sport, profession or business in a manner that exemplifies appreciation of God, country, society, family and self, not only for the sport, profession or business involved, but to the men, women and children whose lives are enhanced by emulating those standards.
Congratulations to Bob Uecker on receiving this prestigious award; he has truly captured the spirit of commitment and pursuit of excellence, standards which define the legendary coach Vince Lombardi and the Vince Lombardi Cancer Foundation.
Robe Warriors: Brewers Starters Sport Personalized Robes Thanks to Matt Garza
Yesterday, we released this photo of Brewers starting pitcher Kyle Lohse sporting a customized bathrobe with "Brewers" on the front and his name and number on the back:
The robe was a gift from fellow starter Matt Garza, who purchased one for each of the starting pitchers prior to reporting to camp.
After posting the photo of Kyle, we received lots of feedback and the story got picked up by numerous media outlets, so this morning, I caught up with Matt to get the story behind the robe:
Fox Sports Wisconsin and the Milwaukee Brewers Announce 2015 Telecast Schedule
FOX Sports Wisconsin and the Milwaukee Brewers today announced a 150-game television schedule for the 2015 season. FOX Sports Wisconsin will serve as the exclusive, local television home for the Milwaukee Brewers.
FOX Sports Wisconsin's regular season coverage begins Monday, April 6, with the Brewers home opener against Colorado — the first of six televised games against the Rockies. Coverage will begin at noon with a special one-hour edition of Brewers Live from Miller Park.
Other highlights from the 2015 schedule include: nineteen games against divisional rival Chicago Cubs, seventeen match-ups against the St. Louis Cardinals, two series with the Minnesota Twins scheduled for June 5-7 and 26-28, as well as five games against the defending World Series champion San Francisco Giants.
Brian Anderson will continue to serve as the primary play-by-play announcer with Matt Lepay joining analyst Bill Schroeder in the broadcast booth for select telecasts. Craig Coshun also will serve as play-by-play announcer for select telecasts, while continuing his role as the main host for Brewers Live pre and postgame shows. Brewers Live airs before and after Brewers telecasts with Jeff Grayson, Telly Hughes and Sophia Minnaert reporting, as well as analysis from former first base coach Davey Nelson and former Brewer Jerry Augustine.
As previously announced, FOX Sports Wisconsin also will televise a total of 12 Brewers spring training games in 2015 beginning Thursday, March 5, with a match-up against the Los Angeles Angels of Anaheim. For the complete schedule, click here.
FOX Sports Wisconsin reaches more than 1.5 million homes and telecasts nearly 2,600 hours of locally produced programming per year. For more information on the Emmy Award-winning regional sports network, visit: FOXSportsWisconsin.com
Bobbles of the Month Are Back for 2015; First Up: The Ballpark Pup
Last season, the Brewers Team Store released limited edition bobbleheads available for fans to purchase.
These bobbleheads were such a hit that they're doing it again. The 2015 Mascot Bobble of the Month Series will feature seven bobbles, with one new bobble being released each month, March – September.
The first Bobble of the Month is a BobbleHank, which will be available beginning March 5 at the Brewers Team Store at Miller Park AND in Maryvale. It retails for $99.
Only 250 of these bobbles will be sold, so be sure to act quickly to add this limited edition piece to your collection!
For those asking, a supply will be available online at a yet to be determined date; I'll do my best to keep you posted.
Today we announced the return of a unique ticket promotion known as the "Brewers Chance 2 Advance Ticket Plan," which allows fans the chance to upgrade their seats to the next highest ticket category every time the Brewers win.
Only a limited number of plans will be available, and they go on sale tomorrow, Wednesday, March 4. Tickets for this promotion sold out in 2013 and 2014 – the first two years of the promotion – so fans will want to act quickly. Last season, the Brewers won five games during the promotion and fans that purchased this ticket plan advanced to the Loge Infield Box.
Here's how it works: For just $99, you get tickets to nine select Tuesday games at Miller Park, plus the chance to advance all the way to the Field Diamond Box. You start with seats in Bernie's Terrace for all nine games, but with each Brewers win, you upgrade your seating area. On Tuesday, May 12, you'll sit in Bernie's Terrace for the first game of the plan against the Chicago White Sox. If the Crew wins, you'll advance to the next seating tier for the following game in the plan.
Every time the Brewers win, you simply exchange your Bernie's Terrace ticket for a ticket in the next best seating area for only $2. You remain in that seat location until the Brewers win the next game in the plan. If the Brewers don't win, simply exchange your Bernie's Terrace ticket at no cost for a seat in the same section where you last advanced – no backsliding.
Ticket Plan Game Dates:
Tuesday, May 12 vs. Chicago-AL 7:10 p.m.
Tuesday, May 26 vs. San Francisco 7:10 p.m.
Tuesday, June 16 vs. Kansas City 7:10 p.m.
Tuesday, June 23 vs. New York-NL 7:10 p.m.
Tuesday, July 7 vs. Atlanta 7:10 p.m.
Tuesday, July 21 vs. Cleveland 7:10 p.m.
Tuesday, August 4 vs. San Diego 7:10 p.m.
Tuesday, August 18 vs. Miami 7:10 p.m.
Tuesday, September 1 vs. Pittsburgh 7:10 p.m.
Order of Seat Upgrades
- Bernie's Terrace
- Terrace Reserved
- Terrace Box
- Loge Outfield
- Loge Infield
- Club Outfield
- Field Outfield
- Field Infield
- Field Diamond
Ticket upgrades must be done in person at the Miller Park Ticket Office (between Windows 1-12 located behind home plate) anytime between the conclusion of the previous game and the start of the next game in the ticket plan. Box Office hours are Monday through Friday from 9 a.m. – 7 p.m.; Saturdays from 9 a.m. – 5 p.m. and Sundays from 11 a.m. – 5 p.m.
Tickets for this plan will be available tomorrow, beginning at 10 a.m. Tickets can be purchased by calling (414) 902-GAME (4263) or by visiting Brewers.com/advance. Service fees apply.
Today, we announced the launch of a brand new podcast, Brewers on Tap, hosted by broadcaster Jeff Levering. The new podcast will feature all things Brewers including interviews with players and fans, trivia contests, social media updates and much more.
Brewers on Tap will be released weekly and will be free to download. Levering, the newest member of the Brewers broadcasting team, will interview players, speak with fans and members of the front office and talk Brewers baseball. Brewers on Tap will also air audio flashbacks, provide historical Brewers information and answer fan questions. During the season, the new podcast will look ahead at upcoming road trips and preview promotions that will take place at Miller Park.
This is the first podcast that the Brewers have produced. The initial episode will be available for download on Wednesday, March 4. Each additional installment will be released every Wednesday. Fans can listen to Brewers on Tap by visiting brewers.com/podcast. Brewers on Tap will also be available as free download on iTunes.
Scooter Gennett Plays in the Dirt
Over the last few days, the #CactusCrew participated in various photo and video shoots to make sure their images are captured for everything from scoreboard and baseball cards to marketing collateral and TV commercials.
The big "Photo Day" was Friday, but over the last few days, the marketing team was on hand, along with folks from CI Design and Brewers Team Photographer Scott Paulus, to capture additional footage for Brewers TV commercials and stills for use in advertising and marketing materials.
One player in particular was really getting into his photo shoot with Scott:
After posing for awhile, Scooter Gennett decided he wanted to make the photos look a little more…um, authentic:
And of course, we had to GIF it:
Pitchers and Catchers Have Reported….Will You? #CACTUSCREW
Spring Training is finally upon us!
Are you headed to sunny, Phoenix, Arizona to see the Crew in Spring Training? Show us your favorite photo and you could be chosen to win a Brewers prize package!
Create an original photo from Spring Training in Phoenix, Arizona. Then, tweet your photo to us on Twitter and/or post it to Instagram using hashtag #CACTUSCREW for your chance to win!
You'll also want to make sure you follow the #CactusCrew hashtag for Spring Training news, updates and chatter!
And don't forget! You can also upload your photo our Brewers interactive map, presented by Southwest Airlines!
Spring Training tickets are available at brewers.com/springtraining.
If you're not headed to AZ this year, don't sweat it. You can listen to, and even watch, some of the Brewers Spring Training games: click here for the complete Spring Training broadcast schedule.
Brewers Alumni Attend 2015 Arctic Tailgate
Several Brewers alumni were on hand at today's Arctic Tailgate event and our own Jeff Levering spoke to Gorman Thomas, Jerry Augustine, Don August and Larry Hisle to get their impressions on the event and the fan support. Check it out:
<iframe src='http://m.brewers.mlb.com/shared/video/embed/embed.html?content_id=39325283&topic_id=8879232&width=400&height=224&property=mlb' width='400′ height='224′ frameborder='0′>Your browser does not support iframes.
Thanks to all the fans who came out to Miller Park today and for those of you who purchased tickets today- 101,000 tickets were sold, tied for second-highest sold in a single day in team history. View more photos from today's event here.


text:
UWS Observatory
UWS Observatory (Penrith) is located on the Werrington North Campus off the Great Western Highway.
The UWS Observatory (Penrith) is part of the School of Computing Engineering and Mathematics. It is operated by a dedicated team of volunteer staff and student that belong to the Computational Astrophysics Imaging & Simulation (CompAIS) group.
CompAIS run engagement and outreach programs for the public and for primary and secondary schools at the UWS Observatory (Penrith). Also available are teachers' workshops, and specialised group programs.
The programs are designed to enhance and extend learning in Science, Technology, Engineering & Mathematics (STEM) via astronomy and space science.A visit to UWS Penrith Observatory can include listening to fascinating lectures on various aspects of astronomy, 3D astronomy experience, and viewing of the night sky through telescopes including the main 0.6 m telescope. You can also come and listen to special lectures given by some of Australia's eminent and internationally recognised astronomers, physicists and engineers.
For more information, please contact Associate Professor Miroslav Filipovic (Academic), Ain De Horta (Academic) or Roslyn McCourt (Administration) on 02 4736 0135.
UWS Penrith Observatory has released an app - download it now to stay up to date with what's going on at the Observatory and what's going on in the night's sky.
Related Links
- Western Sydney Amateur Astronomy Group (WSAAG) (opens in a new window)
- Macarthur Astronomical Society (opens in a new window)
Mobile options:


text:
Get Instant Pricing with Edmunds Price Promise℠
1Look for "Special Offers" on a specific car
2Get your upfront, locked-in price from the dealer
3Go to the dealership to buy your car with no haggle
Total Reviews
Write a
All Models
2007 Volkswagen Passat Sedan 2.0T 4dr Sedan (2.0L 4cyl Turbo 6M)
I purchased my black 2007 Passat with the 2.0 T engine with the manual 6 speed transmission and the sport package with black leather seats in 2010 as a certified vehicle with about 31K miles. Right now I have just over 120K on it and it runs just like new.
The car corners very well, acceleration is great, breaking is great, I love the manual 6-speed, when you are in a mood and there is a good curvy, hilly road Oh man...
As you will find out later on, the car is more expensive to run due to premium gas and to maintain than an Accord or Camry, but what I can say is it delivers 5 tons of joy to me everyday I drive it.I installed a hitch to it as well and it pulls 2,000 lbs like a breeze.
Read the full review
2007 Volkswagen Passat Sedan 2.0T 4dr Sedan (2.0L 4cyl Turbo 6A)
I think the best way to start this review is with the famous saying *results may vary. I have owned my car for the past 3 years and put over 30k miles on it. In all the time I have owned this car I have only been to the dealer a few times and only for regular maintenance and recalls. I have yet to have to pay a dime out of pocket fixing it. I have also never had my check engine light come on. There are lemons out there but they are usually not hard to spot, just check the Carfax for excessive dealer visits. The car is
incredibly comfortable ride and handling are also superb. If you do your research right and check maintenance records, this car is insane value for the money. Just be careful.
Read the full review
Purchased my Passat a little over a year ago with 77k. Thought this would be a good time to review what I think of this car so far. First off, this is a great driving car. By far the most enjoyable car I have owned as far as handling, engine performance, and road manners. VW has really nailed it with the steering on this car; very precise and accurate with good road feel. Also, the 4cyl engine in this car is very smooth with lots of power on tap. No turbo lag whatsoever. As for the minor glitches; main LCD dash display is starting to fade in/out and both power window switches on the driver's door that control the back windows only work intermittently. Typical German car wiring issues.
Read the full review
After having it for not even a year. The Ambient Sensor was reading -5 degrees in 100 degree temp. When my sensor was reading wrong my AC would not blow out cool air. Car was in shop for about a month. 2 months later its back in the shop for the smae issue. This time they replaced the Instrument Cluster. So far its ok, BUT now my GasCap light goes on every morning and when I go to start my car it struggles to start. The moonroof doesnt close all the way sometimes. The car shakes now when its in park... The list goes on! I dont put the cheap gas either I put Chevron gas Premium. This is the MOST inconvenient car i have ever bought! I cant wait until I can pay it off to buy a Infiniti!!!
Read the full review
Bought my 07 12 months ago with 85,000 and put 20,000 on it. Only have needed oil changes, the check engine light does come on now and then but thats VW. Just took it on a 1200 mile trip with 90s to 100 degree heat
and performed beautifully. Just a great car to drive!
Read the full review
2007 Volkswagen Passat Sedan 2.0T Wolfsburg Edition 4dr Sedan (2.0L 4cyl Turbo 6A)
Maybe I am just anothr "lucky one", but I love my 2007 Passat. Prior to this VW I owned a 2000 Passat that I drove to 168k miles that had NEVER been in the shop for any repairs other than general maintenance. This 2007 car has NEVER been in the shop excluding brake maintenance and two recalls that did have to do with the computer system. Overall I think these cars are a great value, fun to drive, get good gas mileage, and the maintenance expenses are reasonable.
Read the full review
2001 model, 275K, 2nd set of brakes, only repair other than maintenance was tie rod ends. Virtually flawless. Now have a 2007 model, 160K, much stronger engine, fun to drive. No mechanical issues. Biggest issue is the VW dealership in Franklin, TN but the car(s) have been great. Maybe I have been lucky but seriously, no issues. BTW, still on the first set of brakes on the front and second on the rear with 160K. Stepping up to the Audi version with the next car because of the dealership, not the car.
Read the full review
2007 Volkswagen Passat Sedan 3.6L 4dr Sedan (3.6L 6cyl 6A)
I bought this as a never-titled demo with 5,000 miles on it. I am knocking wood as I say this, but I have not had the first problem with this car, after 75,000 miles. It's my second Passat V6, and is absolutely the best car I have ever owned. I had an 04 Passat V6, which was really fun to drive, but after warranty it began to have issues. The 07 is a better model, I think, though the steering is not as tight as the 04 due to the widened body.
I took the 07 Passat to the dealer for regular service, but when the warranty expired, I just started having the oil changes done at Jiffy Lube. I think it's not good for a car to be tinkered with too much (i.e., if it ain't broke...). Excellent car.
Read the full review
I got my 2007 Passat almost 4 years ago 'used' (only 6 miles- it was a dealers show car) At first, it was great. However after about 2 years it started having issues. The check engine light was constantly on. I took it to two different VW dealerships to have it fixed a total of 4 times, every time getting a rental car and half the time they said there was no issue, twice they replaced the CV boots (in the matter of 3! months!!!) It died on my way to my parents house on christmas for the last time. Apparently after being given a clean bill of health, the drive chain broke and was then ground into my engine. So after spending roughly over $5,000 making sure it was ok, now it is gone. POS!
Read the full review
2007 Volkswagen Passat Sedan 4dr Sedan (2.0L 4cyl Turbo 6A)
I have had several VW all new. The last one was a brand new 2007 passat I bought. Chck engine is constantly on! The inetrior (back) is peeling off even though no one ever sits there. I am in and out of the shop every month! If you get it all fixed then at least I would wake up with a flat tire! This is worst than my first used car which was a beat up saturn!! I will never go near VW again!! Its a cheap product and I puke when I see it. It's paid off and I am looking for a new car but I would rather ride the train than to buy another cheap behind german product. My husband bought a used BMW at the same time that I bought mine and he has had no problems at all..I am totally done with VW!!
Read the full review
This is the estimated average annual insurance premium being charged in your state. The premium has been determined based on annual premium data for defined coverages (liability, comprehensive and collision) from a major insurer.
While this information is specific to vehicle make, model, model year and body type, your personal information is not taken into consideration and could greatly alter the actual premium quoted by an insurer. Factors that will affect your rate include your age, marital status, credit history, driving record, and the garaging address of your vehicle.
The Edmunds TCO®
data for
this vehicle coming soon...
For an accurate quote, contact our trusted partner on the right.
See which cars and trucks our editors recommend
Write a review and rate your own car.
Help |
About Us |
Contact Us |
Careers |
Affiliate Program |
Dealer Center |
Privacy Statement |
Visitor Agreement |
Membership Agreement
Your Ad Choices
| Site Map
| Glossary
| Mobile
| Developers
Follow Edmunds
© Edmunds.com, Inc.
† Edmunds.com received the highest numerical score in the proprietary J.D. Power 2014 Third-Party Automotive Website Evaluation Study℠. Results based on responses from 3,381 responses, measuring 14 companies and measures third-party automotive website usefulness among new and used vehicle shoppers. Proprietary study results are based on experiences and perceptions of owners surveyed from January 2014. Your experiences may vary. Visit jdpower.com.


text:
Original Paper
Thermoelectric properties of Mg2Si coatings deposited by pack cementation assisted process on heavily doped Si substrates
Article first published online: 9 APR 2014
DOI: 10.1002/pssa.201300140
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
physica status solidi (a)
Volume 211, Issue 6, pages 1308–1314, June 2014
Additional Information
How to Cite
Stathokostopoulos, D., Stefanaki, E. C., Ioannou, M., Polymeris, G. S., Chaliampalias, D., Pavlidou, E., Kyratsi, Th., Paraskevopoulos, K. M., Vourlias, G. and Hatzikraniotis, E. (2014), Thermoelectric properties of Mg2Si coatings deposited by pack cementation assisted process on heavily doped Si substrates. Phys. Status Solidi A, 211: 1308–1314. doi: 10.1002/pssa.201300140
Publication History
- Issue published online: 11 JUN 2014
- Article first published online: 9 APR 2014
- Manuscript Accepted: 4 MAR 2014
- Manuscript Revised: 25 NOV 2013
- Manuscript Received: 20 MAY 2013
Funded by
- European Commission
- European Space Agency
- Individual Partner Organizations
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!


text:
Have to wonder if the FFL's have a hand in this. Either they force the private sellers underground or out of business, or they make money by charging for their services.
Pinellas sheriff to revive enforcement of county law closing 'gun-show loophole
Peter Jamison, Times Staff Writer
CLEARWATER — Pinellas County Sheriff Bob Gualtieri on Tuesday announced plans to strictly enforce a county law mandating background checks for all customers at gun shows, asserting local control in an area that has stubbornly resisted state and federal regulation.
Gualtieri's initiative comes in response to a Tampa Bay Times story last month on the ineffectiveness of local laws closing the so-called "gun-show loophole." The Times reported that while seven of Florida's most populous counties — including Pinellas and Hillsborough — have ordinances requiring background checks for all sales at gun shows, the laws are largely ignored.
According to Gualtieri, that will no longer be the case in Pinellas County. He said that Sheriff's Office deputies, after extensive consultation with the federal Bureau of Alcohol, Tobacco, Firearms and Explosives, plan to monitor upcoming gun shows either in uniform or through undercover operations.
"We're going to make sure the ordinance is enforced," Gualtieri said. "The last thing in the world that I want to see, and I hope anyone wants to see, is a firearm fall into the hands of a person who's prohibited by law from possessing one."
The first gun show to be monitored will be held this weekend at the Minnreg Building in Largo. Organizer Guy Lemakos, a licensed St. Petersburg gun dealer, said he plans to personally perform background checks on behalf of the roughly 25 private vendors at the show, which will feature 120 vendors overall.
Lemakos said he would follow whatever guidelines the Sheriff's Office gives him on complying with the local regulations, but that he thinks the ordinance is poorly conceived and unfairly requires gun-show organizers to police their vendors. He said he would prefer that background checks be run directly by law enforcement, but that agencies have rejected his request that they do so.
"I'll do what I have to do, but I'm uncomfortable with it, because I'm not a cop," he said. "It's not the responsibility of a gun-show owner to enforce the law."
On Monday, Gualtieri sent Lemakos a letter to "remind" him of his vendors' responsibilities under the ordinance.
"We hope there will be voluntary compliance with Pinellas County's background check law and that enforcement of the ordinance will not be necessary," the sheriff wrote.
Gualtieri said he hopes that gun show vendors and organizers will willingly follow the law, which requires that unlicensed firearms sellers — who are not regulated by state or federal law — run background checks on their customers. The checks are supposed to be processed through third-party, licensed gun dealers, who have access to a federal database of criminal and mental-health records.
Pinellas County Commission Chairman Ken Welch praised the sheriff's effort, saying he and Gualtieri had discussed how to enforce the gun-show ordinance in the days after the Times story was published last month. Welch said he had been aware the ordinance was on the books, but didn't know that it was not being actively enforced.
"I commend the sheriff for really taking a proactive stance on this once the information came out," Welch said. "It's not a cure-all, but it is addressing a loophole in the law. I think it's just another step to have reasonable laws for gun safety."
In 1998, Florida voters overwhelmingly supported a state constitutional amendment that allowed counties to require background checks for private gun sales on "property to which the public has the right of access," language that targeted gun shows.
The vote was influenced by Hank Earl Carr, a convicted felon from Tampa who acquired guns despite his criminal record. In May 1998, Carr fatally shot a 4-year-old boy, two Tampa police officers and a Florida Highway Patrol trooper before killing himself.
Federally licensed gun dealers who appear at shows must run background checks on buyers. However, the expositions also tend to attract private sellers, who are not regulated under any state or federal law and can thus sell to customers without checking their criminal histories.
Today, seven Florida counties encompassing close to half the state's population — Pinellas, Hillsborough, Miami-Dade, Broward, Palm Beach, Sarasota and Volusia — have ordinances closing the gun-show loophole.
Despite the fanfare that attended the 1998 state constitutional amendment and later passage of the ordinances, the laws have been virtually unenforced in those counties, the Times found last month.
Have to wonder if the FFL's have a hand in this. Either they force the private sellers underground or out of business, or they make money by charging for their services.
"Taking the gun off safe increases velocity 100%"
Doesn't sound like it's the dealers having any input in this matter. It's a response from the sheriff for the law not being changed to close the loop hole
The mind is the limiting factor
Stay Sharp
I may be way off base but would this fall under pre-emption. If so wouldn't the county laws be illegal.
Ruger SR9c-EDC
Ruger SR22
Mosin Nagant
Romanian AK47 wasr10
The collection is growing...
The article lists seven counties that allegedly have an ordnance. Anyone know if the list is accurate? I thought Orange did and Volusia didn't.
"Today, seven Florida counties encompassing close to half the state's population — Pinellas, Hillsborough, Miami-Dade, Broward, Palm Beach, Sarasota and Volusia — have ordinances closing the gun-show loophole."
There are only 3 colors, 10 digits, and 7 notes; it's how we arrange them that is important.
Want to close the "gun show loop hole" and stop law abiding from selling to felons inadvertently. Tattoo FELON in bright letters on the face of those who lost their right to a firearm before releasing them from prison. It would stop the law abiding citizen from selling to a felon unknowingly in a private sale and be an instant background check. No need to worry about fake ID's or an alias.
If you walk out of your house carrying your gun and you DO NOT fully understand the law, then you are NOT completely armed.
The privilege against self-incrimination is neither accorded to the passive resistant, nor the person who is ignorant of his rights, nor to one indifferent thereto. It is a fighting clause. Its benefits can be retained only by sustained combat. It cannot be claimed by attorney or solicitor. It is valid only when insisted upon by a belligerent claimant in person. McAlister v. Henkel, 201 U.S. 90, 26 S.Ct. 385, 50 L.Ed. 671; Commonwealth v. Shaw, 4 Cush. 594, 50 Am.Dec. 813; Orum v. State, 38 Ohio App. 171, 175 N.E. 876. The one who is persuaded by honeyed words or moral suasion to testify or produce documents rather than make a last ditch stand, simply loses the protection. Once he testifies as to part, he has waived his right and must on cross examination or otherwise, testify as to the whole transaction. He must refuse to answer or produce, and test the matter in contempt proceedings, or by habeas corpus. The holdings in the cases of this type cited by defendant are sound, but they do not apply here because Memolo did not resist, he acquiesced. Likewise, he did not have himself held in contempt or arrested for refusal. Furthermore, he had the documents in his possession and returned them. Finally, he did testify as to such matters many times before this grand jury and now expressly waives the privilege against self-incrimination as to this testimony.
United States v. Johnson, 76 F. Supp. 538, 539 (D. Pa. 1947)
MSgt, USAF, Ret.
Executive Director, Florida Carry, Inc.
NRA Certified Instructor, Pistol, Rifle, Shotgun, PPITH
NRA Certified Chief Range Safety Officer
Glock 23 RTF2
Mosin Nagant M91/30 (1942 Izhevsk)
Stag Arms Model 1
Want to accomplish something for your gun rights?
MSgt, USAF, Ret.
Executive Director, Florida Carry, Inc.
NRA Certified Instructor, Pistol, Rifle, Shotgun, PPITH
NRA Certified Chief Range Safety Officer
Glock 23 RTF2
Mosin Nagant M91/30 (1942 Izhevsk)
Stag Arms Model 1
Want to accomplish something for your gun rights?
"Our civilization is still in a middle stage, no longer wholly guided by instinct, not yet wholly guided by reason." Theodore Dreiser, American author (1871-1945)


text:
Summary of findings [Explanations]
Please refer to an additional table for definitions of clinical terms ( Table 1).
Description of the condition
Definition and clinical features
Sickle cell disease (SCD) is one of the most common and severe genetic disorders in the world. The term SCD covers several common genotypes (Rees 2010; Steinberg 2011).
- Sickle cell anaemia: homozygosity for the sickle haemoglobin gene (HbS). This is the most prevalent form of SCD and is caused by inheritance from both parents of an HbS gene.
- Sickle cell-haemoglobin C (HbSC) disease: compound heterozygosity for HbS and haemoglobin C (HbC) genes. This second most common type of SCD is caused by inheritance of one sickle cell gene from one parent and another abnormal haemoglobin gene (HbC) from the other.
- HbS–β-thalassaemia: compound heterozygosity for HbS and a β
0-or β +-thalassaemia gene (Sβ 0, Sβ +). The third major type of SCD, caused by inheritance of one sickle cell gene from one parent and one β 0-or β +-thalassaemia gene from the other.
- Other double heterozygous conditions such as haemoglobin SD disease (HbSD), haemoglobin SE disease (HbSE), etc.
Homozygous sickle cell (SS) disease and sickle cell/β
Individual heterogeneity between people with SCD makes clinical manifestations of the diseases highly variable in frequency and severity, ranging from completely asymptomatic cases to very severe forms. However, most patients (about 70%) have a moderate phenotype (Inati 2009).
Sickle cell diseae can be broadly divided into distinct clinical phenotypes characterised by either haemolysis or vaso-occlusion (Ballas 2010; Ballas 2012; Inati 2009). During haemolysis the red blood cells lyse prematurely and the content of the cells, that is, the haemoglobin, is released into the surrounding fluid; during vaso-occlusion the sickled red blood cells clump together, obstructing blood flow and damaging corresponding tissues and organs. Vaso-occlusion leads to both acute and chronic complications (Mousa 2010). Clinical manifestations of vaso-occlusion include acute episodes of severe pain (crises); acute chest syndrome (a life-threatening pneumonia-like illness); increased infections; joint necrosis; stroke; spontaneous abortion; and multi-organ failure (Ballas 2010; Ballas 2012; Ballas 2013; Inati 2009; Mousa 2010; Steinberg 1999). Chronic haemolysis manifests clinically as anaemia, cholelithiasis (presence of gall stones), pulmonary hypertension, priapism (painful persistent erections), leg ulceration, sudden death, and possibly stroke (Gladwin 2012; Inati 2009b). However, the severity of the clinical manifestations depends on the degree of haemolysis, and those with less haemolysis are predicted to have pain crises, acute chest syndrome, and osteonecrosis (Bunn 2010). According to Bunn and colleagues, pulmonary hypertension is usually minor and is confounded by several co-morbid conditions including high cardiac output, pulmonary vascular inflammation and occlusion (thrombosis in situ, fat embolism), as well as left ventricular failure (Bunn 2010). A comprehensive overview of clinical signs and symptoms is provided in a article by Ballas 2010, in which clinical manifestations are divided into three groups; haemolytic anaemia and its sequelae, pain syndromes and related issues and complications in major organs and related co-morbidities. Morbidity and mortality in people with SCD mainly result from tissue infarction (tissue death due to oxygen shortage) secondary to obstruction of the small blood vessels by sickle cells (Davies 2012).
Pain is the hallmark of SCD (Ballas 2013; de Montalembert 2008; Steinberg 2011). It can be acute or chronic and most often is located in joints, extremities, back or chest, but pain can occur anywhere and can last several days or weeks, or longer (de Montalembert 2008; Steinberg 2011). The frequency and severity of painful episodes vary widely within and between individual patients (de Montalembert 2008; Steinberg 2011). Acute chest syndrome is characterised by fever, cough, sputum production, tachypnoea (rapid breathing) and dyspnoea (breathing difficulties) and is the second most common reason for hospitalisation in this group of patients after pain (Ballas 2010; Ballas 2013; de Montalembert 2008; Steinberg 2011).
Patients are more susceptible to infection; in children the most prevalent agent is Streptococcus pneumoniae, and in adults gram-negative organisms are more common (de Montalembert 2008; Steinberg 2011). Fatigue and shortness of breath are symptoms of pulmonary hypertension, which is another frequent complication. Strokes occur in approximately 10% of children and adults with sickle cell anaemia but are much less common in other genotypes of the disease (Inati 2009; Steinberg 2011) and can lead to cognitive impairment as a result of neurological changes.
Anaemia manifests as fatigue, dizziness, headache, and cold hands and feet. Other complications associated with SCD include priapism in men leading to painful erections; leg ulcers, which can be both painful and disabling; sight problems due to retinopathy; and renal failure. But in fact all organs can be affected, resulting in organ-specific symptoms and complications (Ballas 2010; Ballas 2012; Ballas 2013; de Montalembert 2008; Steinberg 2011).
Epidemiology and causes
With estimates of approximately 300,000 babies born each year with documented SCD, this is one of the most common genetic inherited diseases worldwide (de Montalembert 2008; Mousa 2010; Rees 2010; WHO 2006). Prevalence is highest among people whose ancestors come from sub-Saharan Africa, India, Saudi Arabia and Mediterranean countries (Rees 2010; WHO 2006), but in our increasingly multi-ethnic world, the disease has become a global problem (de Montalembert 2008; Steinberg 2011; WHO 2006).
Sickle cell disease is caused by inheritance from both parents of a mutation in the beta-globin gene. As a result of this point mutation in the sixth position of the β-globin chain, valine is substituted for glutamic acid, leading to the production of a defective form of haemoglobin (haemoglobin S (HbS)) (De Franceschi 2011; Inati 2009b; Mousa 2010). Upon deoxygenation, HbS polymerises to the sickle form with distorted, sickle-shaped dehydrated red blood cells (Inati 2009b). Sickle erythrocytes occlude blood vessels of all sizes (Steinberg 2011), causing a spectrum of clinical manifestations, in addition to haemolysis and anaemia (Mousa 2010). It can cause severe pain crises and progressive organ damage to virtually every organ system in the body, and it is associated with a reduced life expectancy (Mousa 2010; Rees 2010; WHO 2006).
Description of the intervention
Low-molecular-weight heparins (LMWHs) act through the antithrombin inhibition of Factor Xa more than Factor IIa (thrombin) and have greater bioavailability and longer duration of action than unfractionated heparin (Hoy 2010) (see Table 2 for the classes of anticoagulants). At a higher dose, LMWHs are used to treat active thrombotic diseases such as deep vein thromboses, pulmonary emboli, or both, and they are used at lower doses to prevent thrombosis. The LMWHs have a more predictable anticoagulant response than unfractionated heparin, allowing them to be administered in fixed, weight-based dosages without routine laboratory monitoring, thus facilitating outpatient therapy (Hoy 2010). Conducting a systematic review of the effectiveness and safety of LMWHs is warranted because hypercoagulability in SCD is a well-established pathogenic phenomenon (Ataga 2012).. Several studies have suggested the use of tinzaparin (one of the commonly used LMWHs) to control the hypercoagulable state of SCD, but none have provided solid evidence to support or discourage the use of LMWHs (De Franceschi 2009; Hirani 2011; Mousa 2010; Qari 2007).
How the intervention might work
The pathophysiology of SCD has many facets, and no single treatment addresses all consequences of the disease. Hence, for treatment of patients with SCD, a combination of several interventions, depending on the expression of disease-specific features and complications, is necessary. In addition to standardised pain management (de Montalembert 2008; Mousa 2010; Rees 2010; Steinberg 2011), alternative approaches to therapy that have anti-adhesion, anti-inflammatory and anticoagulant effects have been proposed (Mousa 2010).
The LMWHs exert their major anticoagulant effect by binding to antithrombin via a pentasaccharide, consequently inactivating Factor Xa and Factor IIa (Hirsh 1992; Hirsh 2001; Mousa 2003). Furthermore, LMWHs have anti-inflammatory properties in addition to their anticoagulant properties (Carr 2007), in part caused by suppression of tumour necrosis factor-α, which is released during blood clotting, and in part because of binding to P-selectin to inhibit leukocyte migration. Vaso-occlusion also leads to an altered nitric oxide (vasodilator) metabolism and contributes to vascular dysfunction (Mousa 2010), whereas LMWHs increase nitric oxide production and enhance vasodilating effects.
Why it is important to do this review
Management of vaso-occlusive crises is complicated and may require multiple strategies and interventions. However, we are unaware of the existence of a current systematic review undertaken to examine available evidence for the benefits and harms of LMWHs.
To assess the effects of LMWHs in managing vaso-occlusive crises in patients with SCD.
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials (RCTs) and controlled clinical trials (CCTs).
Types of participants
People with SCD SS, HbSC, Sβ
Types of interventions
Any LMWH administered subcutaneously compared with placebo or standard care for a period of up to two years.
A post hoc change has been made to the protocol to include all LMWHs rather than just one (tinzaparin), as was previously included. This change is intended to provide a more comprehensive review of this treatment area.
Types of outcome measures
Primary outcomes
- Pain
- Intensity (expressed as scores obtained through any validated patient-reported outcomes instrument, either generic or SCD specific)
- Duration
- The requirement for opiate treatment
- Dose
- Type
- Frequency
Secondary outcomes
- Number of serious complications of SCD (e.g. stroke, acute chest syndrome, infection, acute splenic sequestration).
- Number of other sickle-related events (e.g. priapism, leg ulceration).
- Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific.
- Hospitalisation (number and duration).
- Participant satisfaction with the medication as assessed by any appropriate and validated questionnaire (either generic or SCD specific).
- Adverse events associated with the use of anticoagulants (e.g. bleeding).
Search methods for identification of studies
Electronic searches
Authors identified relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms (bemiparin* OR certoparin* OR nadroparin* OR parnaparin* OR reviparin* OR ardeparin* OR danaparoid OR tinzaparin* OR dalteparin* OR enoxaparin* OR fondaparinux) AND (sickle cell OR haemoglobinopathies general).
The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and from quarterly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group Module.
Date of the last search of the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 06 December 2012.
Searching other resources
The following additional resources were used:
- the bibliographical references of identified studies for citations to additional studies (EvZ, 4 January 2013);
- personal contact with corresponding authors of relevant trials or review authors and other experts (EvZ);
- clinical trials registries: ClinicalTrials.gov; Current Controlled Trials (across multiple registers) using the search terms (low-molecular-weight heparin OR sickle cell OR crises) AND trial (EvZ, 4 January 2013);
- conference proceedings of the International Society of Thrombosis and Hemostasis (ISTH) and of the Scientific Subcomittee of the ISTH (EvZ, 10 January 2013).
Data collection and analysis
Selection of studies
Two review authors (EvZ and ZF) independently assessed the abstracts of trials resulting from the searches. They obtained full-text copies of all relevant and potentially relevant trials, those appearing to meet the inclusion criteria and those for which details in the title and in the abstract were insufficient to allow a clear decision. The two review authors then independently assessed the full-text articles. Any disagreements on the eligibility of trials were resolved through discussion and consensus. All irrelevant records were excluded, and details of the trials and the reasons for their exclusion were noted in the Characteristics of excluded studies in RevMan 5.1 (RevMan 2011).
Data extraction and management
Two review authors (EvZ, ZF) entered details for the included trials into the tables in the 'Characteristics of included studies' in RevMan 5.1 (RevMan 2011) and collected outcome data using a pre-determined form designed for this purpose. Two review authors (EvZ, ZF) extracted data independently and in duplicate and included them if consensus was reached. Trial investigators were contacted and were asked to provide missing data or to clarify study details (see Table 3).
The review authors extracted the following details.
- Trial methods
- sequence generation
- method of concealment of allocation
- masking of participants, trialists and outcome assessors
- exclusion of participants after randomisation and proportion and reasons for losses at follow-up
- Participants
- country of origin and study setting
- sample size
- age
- gender
- inclusion and exclusion criteria
- Intervention group
- type of LMWH
- dose and frequency
- duration of intervention and follow-up
- Control group
- dose and frequency
- duration of intervention and follow-up
- Outcomes: primary and secondary outcomes mentioned in the 'Types of outcome measures' section of this review and categorised and grouped accordingly: short-term data at 3, 6 and 12 months and medium- to long-term data (beyond one year).
If stated in the trial reports, the review authors recorded the sources of funding of all included studies and used this information to help in assessment of the clinical heterogeneity and external validity of all included trials.
Assessment of risk of bias in included studies
Two review authors (EvZ, ZF) independently assessed the selected trials using a simple contingency form and in accordance with the domain-based evaluation described in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions 5.1 (Higgins 2011a). The review authors compared evaluations and discussed and resolved any inconsistencies in these evaluations.
The review authors assessed the following domains as having low, unclear or high risk of bias:
- sequence generation;
- allocation concealment;
- blinding (of participants, personnel and outcome assessors);
- incomplete outcome data addressed;
- free of selective outcome reporting;
- free of other bias.
The review authors reported these assessments for each trial in the 'Characteristics of included studies' tables and in the 'Assessment of risk of bias in included studies' section of this review.
The authors categorised and reported the overall risk of bias of each of the included studies according to the following:
- low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria met;
- unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria assessed as unclear; or
- high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria not met.
Measures of treatment effect
The review authors sought advice from the Cochrane Cystic Fibrosis and Genetic Diseases Group with regard to statistical analysis for data synthesis. They analysed the data using RevMan 5.1 and report the results according to Cochrane Collaboration criteria (RevMan 2011). The authors analysed binary data and report risk ratios (RRs) with corresponding 95% confidence intervals (CIs); they also analysed continuous outcomes and report mean differences (MDs) between treatment groups and their 95% CIs. For future updates, if different scales or different units are collected for continuous outcomes, the review authors will calculate and present the data using the standardised mean difference (SMD). In addition, for repeated observations for individual participants and for events that may recur, the authors will follow Chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011c).
Unit of analysis issues
In future updates, if cluster-randomised or cross-over trials are included, they will be checked for unit of analysis errors based on the advice provided in Chapters 16.3.4 and 16.4.4 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011d). For repeated observations per participant and for events that may recur, the review authors will follow guidance provided in Chapters 9.3.4 and 9.3.5, respectively, of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011d).
Dealing with missing data
The review authors contacted principal investigators of included trials to request missing data and followed the advice provided in Chapter 16.1 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011d) (see Table 3).
Assessment of heterogeneity
The review authors will assess in future updates (when more studies are included) clinical diversity between trials by examining trial characteristics, similarities between types of participants, the interventions and the outcomes as specified in the inclusion criteria.
They will explore statistical heterogeneity using a Chi
Assessment of reporting biases
In view of the low number of trials included, this assessment was not undertaken. In future updates, and if a sufficient number of trials (at least 10) assessing similar interventions are identified for inclusion in this review, the review authors plan to assess publication bias according to the recommendations on testing for funnel plot asymmetry as described in Chapter 10 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b). If asymmetry is identified, the review authors will attempt to assess other possible causes, and these will be explored in the discussion section of the review if appropriate.
Data synthesis
Two review authors (ZF, EvZ) analysed the data in RevMan 5.1 (RevMan 2011) and reported them as specified in Chapter 9 of the Cochrane Handbook for Systematic Reviews of Interventions 5.1 (Higgins 2011c). They used a fixed-effect model to analyse data from studies, unless in future updates they plan to identify moderate or higher heterogeneity (see classifications above), in which case they will use a random-effects model to analyse data.
Subgroup analysis and investigation of heterogeneity
In future updates, if a sufficient number of trials are included and if the authors identify moderate, substantial or considerable heterogeneity (see 'Assessment of heterogeneity'), they plan to carry out the following subgroup analyses based on:
- type of LMWH;
- type of SCD: sickle cell anaemia; haemoglobin SC disease; sickle cell β
0-thalassaemia; sickle cell β +-thalassaemia;
- different dosing schedules.
Sensitivity analysis
The review authors will undertake sensitivity analyses in future updates if a larger number of trials are included, to assess the robustness of their review results by repeating the analysis with the following adjustments:
- exclusion of trials with an unclear or high risk of bias for allocation concealment;
- exclusion of trials with an unclear or high risk of bias for blinding of outcome assessment;
- exclusion of trials with an unclear or high risk of bias for completeness of follow-up;
- exclusion of CCTs.
Description of studies
Results of the search
Study selection was carried out independently by both review authors (EvZ and ZF), who retrieved two studies, one of which was a duplicate. The review authors also identified one ongoing trial (see Characteristics of ongoing studies). For further details, see the 'Study Flow Diagram' (Figure 1).
|Figure 1. Study flow diagram.
Included studies
One study comprising 253 participants was included (Qari 2007, see the 'Characteristics of included studies' section).
Characteristics of the trial setting and methods
The study was a randomised placebo-controlled trial conducted in three hospitals in Saudi Arabia.
Characteristics of the participants
A total of 253 participants (men and women) of around 22 years of age with homozygous SCD and with painful vaso-occlusive crises, severe enough to require narcotic analgesia, were included.
Characteristics of the interventions
Tinzaparin at 175 IU/kg given subcutaneously versus placebo was evaluated over seven days. All participants received standard analgesic therapy consisting of morphine at 1 mg/h given by intravenous infusion and rehydration with normal saline.
Characteristics of the outcome measures
Seven outcome measures were assessed, including pain intensity and duration, as well as complications and adverse events of the therapy (see 'Characteristics of included studies' for further details).
Excluded studies
No studies were excluded; just one study and a duplicate remained after assessment of the titles and abstracts resulting from the searches.
Risk of bias in included studies
The review authors assessed the included study for risk of bias and reported the judgements for the individual domains in the risk of bias table associated with the study. The review authors have also presented these in the risk of bias graph in Figure 2 and in a summary of the risk of bias in Figure 3.
|Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
|Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Sequence generation
The method used to generate the allocation sequence was not described, and the review authors judged this domain as having an unclear risk of bias.
Allocation concealment
The method used to conceal the allocation sequence was not reported, and a judgement of an unclear risk of bias was given for this domain.
Reporting of the measures used to blind study participants and personnel from knowledge of which intervention a participant received was inadequate, as was information on blinding of the outcome assessment. Therefore, a clear judgement could not be made for these domains.
Incomplete outcome data
No losses to follow-up were reported, and this domain was therefore judged as having a low risk of bias.
Selective reporting
Athough the protocol was not available, all pre-specified outcomes appear to have been reported, and this domain was assessed as having a low risk of bias.
Other potential sources of bias
One of the investigators was employed by Leo Pharmaceutical Products (Athens, Greece), the manufacturer of tinzaparin, and a potential risk of bias cannot be excluded.
Effects of interventions
See: Summary of findings for the main comparison Tinzaparin compared to placebo for people with sickle cell disease
Tinzaparin versus placebo
One single study provided data for this comparison (Qari 2007).
Primary outcomes
1. Pain
a. Intensity (expressed as scores obtained through any validated patient-reported outcomes instrument, either generic or SCD specific)
No precise data were reported; therefore, these were estimated from the graph-plot in the report. The authors indicated that at days two and three, the pain severity score was lower in the tinzaparin group than in the placebo group (P < 0.01 (ANOVA)), in addition to that at day 4 (P < 0.05 (ANOVA)), and thus that tinzaparin resulted in more rapid resolution of pain as measured by the numerical pain scale (NMS).
b. Duration
In the tinzaparin group, the duration of painful crises was 2.57 days (standard deviation (SD) 0.45) versus 4.35 days (0.78) for the placebo group; mean difference (MD) -1.78 days (95% CI -1.94 to -1.62), and this difference was statistically significant in favour of tinzaparin ( Analysis 1.1).
2. The requirement for opiate treatment
This outcome was inadequately reported, only that during the study all participants received standard analgesia therapy consisting of morphine at 1 mg/h given via intravenous infusion and rehydration with normal saline.
Secondary outcomes
1. Number of serious complications of SCD
Not assessed.
2. Number of other sickle-related events
Not assessed.
3. Quality of life (e.g. absence from school, lost time at work, mobility) as assessed by any validated questionnaire, either generic or SCD specific
Not assessed.
4. Hospitalisation (number and duration)
Participants treated with tinzaparin had statistically significantly fewer hospitalisation days compared with those in the group treated with placebo. The number of days in the tinzaparin group was 7.08 (SD 1.8), and in the placebo group, the number was 12.06 (2.2), MD -4.98 days (95% CI -5.48 to -4.48) ( Analysis 1.2).
5. Participant satisfaction with the medication assessed by any appropriate and validated questionnaire (either generic or SCD specific)
Not assessed.
6. Adverse events associated with the use of anticoagulants (e.g. bleeding)
Two minor bleeding events were reported in the tinzaparin group compared with none in the placebo group, RR 4.96 (95% CI 0.24 to 102.31); P value = 0.30). The difference was not statistically significant ( Analysis 1.3).
Summary of main results
One study at unclear to high risk of bias, which examined 253 participants, was included. This study reported that tinzaparin reduced hospitalisation days and pain, as well as pain intensity, more rapidly when compared with placebo. The review authors identified an ongoing trial that, although it is investigating the effects of another LMWH dalteparin, will address several common outcome measures and may contribute to the body of evidence (NCT01419977).
For further details, see the ' Summary of findings for the main comparison'.
Overall completeness and applicability of evidence
Incomplete evidence was found to support or refute the effectiveness of LMWHs for the management of vaso-occlusive crises in individuals with SCD. Although adequately powered, the single trial included in this review failed to address the majority of clinically relevant secondary outcomes, not least of all change in 'quality of life' and patient satisfaction; this somewhat limits the applicability of the evidence generated. However, the low number of adverse events reported appeared to illustrate the relative safety of the use of tinzaparin, albeit only over a short period of treatment time. The single ongoing study that was identified may eventually help to fill in some of the gaps in evidence for the effectiveness of LMWHs in managing vaso-occlusive crises.
Quality of the evidence
Limitations in study design and implementation
Although the study design of the included study appeared to have been at best adequate, our assessment of the risk of bias for several domains in this study revealed some of the limitations in its implementation, which have been reported in the 'Risk of bias in included studies' section of this review. In particular, after unsuccessful attempts to contact the investigators in this study, the methods used to generate the sequence and to conceal the allocation and the measures taken to blind investigators and participants remained unclear. Pain intensity and duration are key outcomes and require accurate assessment with the use of a valid and reliable tool. The NMS pain scale used in the study did not appear to meet these criteria, making it difficult for the review authors to interpret the value of the reported outcomes and to further translate these into clinical practice.
Indirectness of the evidence
Participants in the included study in general constituted a clinically representative sample, matching the inclusion criteria; therefore, the review authors had no significant concerns about the appropriateness of including participants identified in the review.
Placebo-controlled rather than head-to-head trials are still required to evaluate whether LMWHs have any beneficial effect on vaso-occlusive crises. These trials should also consider evaluating other LMWHs.
The study addressed several of our predefined outcomes; however, evidence was lacking on a requirement of opiates for pain relief and of participants' assessed outcomes (e.g. health-related quality of life (HRQOL) and participants' level of' satisfaction). Patient-relevant outcomes are a pre-requisite for informing evidence-based clinical decision making, but the importance of patient-reported outcomes (PROs), specifically those used in evaluating the impact of the intervention on quality of life, appears to have been underestimated by the investigators in the included study.
Inconsistency of the results
As only one study was included, assessment of inconsistency was not feasible.
Imprecision of the results
Only one study was included.
Publication bias
Although our attempts to identify additional studies were unsuccessful, the possibility of unpublished research on this topic cannot be excluded. In future updates, and if further trials are identified for inclusion, we will assess publication bias as specified in the Assessment of reporting biases section of this review.
Potential biases in the review process
We made every attempt to limit bias in the review process by ensuring a comprehensive search for potentially eligible studies. The review authors' independent assessments of eligibility of studies for inclusion in this review minimised the potential for additional bias.
Agreements and disagreements with other studies or reviews
A number of literature reviews have described a range of management strategies for sickle cell disease-related vaso-occlusive crises; the most recent and relevant for our review is Mousa 2010, which referred to the only RCT (Qari 2007) identified in this systematic review and indicated that treatment with tinzaparin is "justified in the treatment of acute painful crisis in SCA based on that randomized controlled trial". The report specifies tinzaparin as adjuvant therapy in its "evidence based recommendations for pain management" but provides no indication of any systematic search of the literature, nor a critical appraisal of the cited references, but rather states that these recommendations are based on the "long term experience" of a panel of physicians and scientists.
Several studies have suggested the possible use of tinzaparin to control the hypercoagulable state occurring in SCD (De Franceschi 2009; Hirani 2011; Mousa 2010), but all were based on one study (Qari 2007). Whilst these investigators recognize its potential use in managing vaso-occlusive crises, they concur that it is still an experimental treatment option and provide no general recommendation as long as further studies have not been conducted.
Authors' conclusions
Implications for practice
Current recommendations and practices for the management of vaso-occlusive crises in people with SCD continue to be largely based on clinicians' judgement. However, the results of this review demonstrate that at present, high-level objective evidence is insufficient to support reliable clinical decision making regarding the use of LMWHs in patients with SCD.
Implications for research
This review highlights the need for further randomised placebo-controlled trials to evaluate the effects of LMWHs in the management of vaso-occlusive crises in patients with SCD, which can ultimately provide reliable evidence to help inform clinical decision making.
Studies with other types of LMWHs, as well as in participants with different genotypes of SCD, still need to be carried out to confirm or dismiss the results reported by this single study.
Any future RCTs must be well designed, well conducted and adequately delivered with subsequent reporting, including high-quality descriptions of all aspects of methodology. Reporting should conform to the Consolidated Standards of Reporting Trials (CONSORT) statement (http://www.consort-statement.org/), which will enable appraisal and interpretation of results, as well as accurate judgements to be made about the risk of bias and the overall quality of the evidence.
Although it is uncertain whether reported quality mirrors actual study conduct, it is noteworthy that studies with unclear methodology have been shown to produce biased estimates of treatment effects (Schulz 1995).
For further research recommendations based on the EPICOT (evidence, population, intervention, comparison, outcomes and time) format (Brown 2006), see Table 4.
The authors would like to thank Amani Al Hajeri, Moiz Bakhiet, Joel Beleno and Nilda Manansala for their contributions to the drafting of this protocol. The authors would also like to thank Tracey Remmington and Nikki Jahnke of the Cochrane Cystic Fibrosis and Genetic Disorders Group for their support in developing this review.
Data and analyses
- Top of page
- Summary of findings [Explanations]
- Background
- Objectives
- Methods
- Results
- Discussion
- Authors' conclusions
- Acknowledgements
- Data and analyses
- History
- Contributions of authors
- Declarations of interest
- Sources of support
- Differences between protocol and review
- Index terms
Protocol first published: Issue 10, 2012
Review first published: Issue 6, 2013
Contributions of authors
EvZ and ZF are responsible for the following:
- designing and co-ordinating the review (EVZ, ZF);
- co-ordinating the review (EvZ);
- organising the retrieval of papers (EvZ);
- writing to authors of papers for additional information (EvZ);
- screening search results (EvZ, ZF);
- screening retrieved papers against inclusion criteria (EvZ, ZF);
- appraising the quality of papers (EvZ, ZF);
- data collection for the review (EvZ, ZF);
- extracting data from papers (EvZ, ZF);
- obtaining and screening data on unpublished trials (EvZ);
- the analysis and interpretation of data (EvZ, ZF);
Both review authors contributed to development of the protocol.
ZF is the guarantor of the review.
Declarations of interest
No financial conflicts of interest have been reported, and the authors declare that they do not have any associations with any parties who may have vested interests in the results of this review.
Sources of support
Internal sources
- No sources of support, Bahrain.
- No sources of support, Netherlands.
External sources
- No sources of support, Netherlands.
- No sources of support, Bahrain.
Differences between protocol and review
A post hoc change was made to the original protocol (before publication of the full review) to include all LMWHs rather than just one (tinzaparin), as was previously included. This was done in an effort to provide a more comprehensive review of this treatment area.
Index terms
Medical Subject Headings (MeSH)
Anemia, Sickle Cell [*complications]; Anticoagulants [*therapeutic use]; Heparin, Low-Molecular-Weight [*therapeutic use]; Peripheral Vascular Diseases [*drug therapy; etiology]; Randomized Controlled Trials as Topic
MeSH check words
* Indicates the major publication for the study


text: A low unemployment rate that beats the state, national and our regional competitors was one bullet presented by Roger Feagley during his State of the Economy presentation to the Sulphur Springs City Council Tuesday night. Feagley said our area better survived the recent economic downturn due to our good mix of primary jobs. He said another factor was owner occupied businesses. Feagley said maybe people should be talking about the Hopkins County miracle like they do the Texas miracle.


text:
- News
- Local
- Sports
- Business
- Politics
- Opinion
- Lifestyle
- Entertainment
- Obituaries
- Classifieds
- Autos
- Housing
- Jobs
REVIEW: "The White Snake" illuminates an old Chinese story about identity, harsh religion and the bonds of love.
Updated: September 15, 2014, - 08:31 AM
A new Web series has made Kate Wetherhead, who stars in the Guthrie's fall production of "The Heidi Chronicles," an underground celebrity in her business. Plus fall theater picks.
Updated: September 12, 2014, - 04:00 PM
REVIEW: Chanhassen Dinner Theatre has revived this slight farce, and, as a night at the museum, "Hello, Dolly!" has its charms.
Updated: September 12, 2014, - 03:40 PM
Twin Cities theater mainstay Jack Reuler defies "types" and practices diversity of spirit and mind. He is artistic director of Mixed Blood Theatre, which has programmed a 2014-15 season full of LGBT themes, African and Muslim plays, a festival of new Arab writing, plays about immigration and people with disabilities. It is the most pluralistic theater season in memory.
Updated: September 12, 2014, - 03:22 PM
Kate Wetherhead, starring in "The Heidi Chronicles" at the Guthrie this fall, has used her brains and drive to get ahead.
Updated: September 10, 2014, - 12:28 PM
"The White Snake" director Mary Zimmerman talks about her fascination with "things deeper than the self."
Updated: September 05, 2014, - 02:46 PM
The family is back together for Chanhassen's production of "Hello, Dolly!"
Updated: September 05, 2014, - 10:52 AM
Interim president is betting team spirit will sell tickets to the first full season in three years, win grass-roots donations and burnish a badly damaged by the longest lockout in American symphonic history.
Updated: August 30, 2014, - 10:14 PM
Renée Fleming, who sings with the Minnesota Orchestra on Friday, has become the friendly face of opera in America.
Updated: August 29, 2014, - 08:47 AM
Actor Stephen Cartmell, the face of a baked bean brand in his native New Zealand, is the new guy in...
Updated: August 28, 2014, - 03:46 PM


text:
First of all, we want you to know that you can believe everything you read here, even if it is April Fool's and we might have told a fib or two elsewhere on the site. Consider the News Desk a hallowed ground. We'll only tell you true facts here. We are indeed going to show you some of our favorite April Fool's pranks from around DeviantArt and around the web, but we won't try to fool you with any of these headlines. Thanks, as always, for reading.
Here are a few of our favorite April Fool's pranks.
Book Club
The CRLiterature book club has "announced" their book selection for the month of April. Some may call it smut, but 50 Shades of Grey is the official selection so if you haven't read it by now, this is the best excuse you're going to get. April Fool's! The real selection will be announced tomorrow.
Harnessing the Force
CERN physicist Valerio Rossetti
CERN Discovers The Force
Researchers at CERN posted confirmation that they had indeed discovered The Force (yes, the one from Star Wars) as a part of a Star-Wars themed April Fool's prank. The press release, which you can read here, went heavy on the references including allusions to Yoda, Ben Kenobi, and "Dave" Vader. Considering the breadth and scope of the research currently being done at the Large Hadron Collider, we think it's a good sign that they know how to have a little fun.
Nature: Dragons Are Real
Another of our favorite April Fool's pranks came out of the science world today, as Nature.com confirmed the existence of dragons. Citing some ancient texts and a correlation between global temperature patterns and references to dragons in literature, nature.com's April Fool's prank is one that we wish were true.
Premium Island
You may be wondering where the money from your premium memberships go, and this April Fool's prank has the answer: that's right, you're looking at the DeviantArt island. Again, this is one that we really wish was true.
by Amazon
Amazon Redesign
Some of the best April Fool's pranks are the ones that offer an experience rather than try to fool you. Yesterday we told you about Google Maps's Pac Man feature, and today we are giving some major snaps to Amazon, who threw back to a super 90s version of their site in honor of this hallowed internet holiday. They also loaded the homepage with a couple of jokes, but then allow users to quickly navigate back to the real site so that they can get back to browsing prices on Lord of the Rings blu-rays with ease.
Learn To Art In A Day
seniormentors has launched a new tutorial series called Learn This and they intend to post one EVERY HOUR! The first one is about Photomanipulation and Digital Painting. By the time they've posted a few more, we should all be masters of art.
Back to your regularly-scheduled programming.
Amazon Button
by Amazon
Amazon Buttons Are A Real Thing
First Amazon giveth and then Amazon taketh away, apparently. While we commend them for their April Fool's efforts, the online megastore has also announced that it will be making branded buttons that automatically order household items that you commonly run out of. With the devices, you can put a little Tide button on your laundry machine, and when you're running low on detergent, you press the button and in two to five business days you receive some more. The announcement was viewed as a joke by many because of its proximity to April Fool's and also because holy cow have we really gotten to the point as a society that we are too lazy to even walk to our computers or god forbid get out our phones to place online orders when we run out of stuff? I mean they already have one-click shopping on Amazon, why do we need this? Excuse us as we bury our heads in the sand for the rest of the day.
It's Poetry Time
Calling all aspiring poets! Today marks the beginning of NaPoWriMo is ON! Your mission, should you choose to accept it, is to write a poem every day for the entire month of April. If you're staring at a blank page, not to worry, SingingFlames has posted some prompts to help you get started.
Suicide Sisters
by Kevin Mellon
Hero Challenge
autodesk-sketchbook has announced the April Hero Challenge with Kevin Mellon, who has been working as a professional comic book and storyboard artist since 2007. He has a comic book called Suicide Sisters, and does storyboards for the TV show Archer. Get information on the challenge here!
Interstellar Honest Trailer
The folks at Screen Junkies have given a pretty spectacular and not entirely undeserved sendup to Christopher Nolan's 2014 blockbuster Interstellar. We aren't going to lie to you, we thoroughly enjoyed that movie, but as usual Honest Trailers does a pretty great job of pointing out some of its fundamental flaws. Plus, it's just hilarious.
What To Wear?
griffsnuff is looking for some feedback concerning her new avatar. Share your thoughts here. (We think it looks great, for what it's worth).
Which Tablet Are You?
This tablet review by saally may prove to be helpful when deciding what tool is going to suit your needs best.
Color Contest
Knitting-and-Crochet has announced a contest celebrating Pantone's colour of the year: Marsala. Get involved here.
Vesta Tour
by NASA
Hang Out On An Asteroid
How is NASA so cool all the time? Probably because they're dedicated to exploring and understanding space. We're mildly freaking out over this virtual tour of Vestra, the second-largest asteroid in our solar system. The tour interface is reminiscent of Google Earth, and has some snazzy features that let you explore and see all there is to see on this huge space rock. This is just so cool.
Forum Feature
Looking for constructive critiques on your digital art pieces? Check out this thread.
Birthday Patrol
It's no April Fool's joke, today is FelipeCagno's birthday. Say hey and happy b-day!


text:
Discover a selection of top forums immigration russian on the internet. Come to share your passion on forums immigration russian and meet other fans of immigration russian. Then, why don't you create your own forum of immigration russian ?
Military Forum for Russian and Global Defence Issues
debate, issues, english, #russian, military, forum, leaders, nuclear, weapons, political, vidoes, photos, russia
Top forex brokers review , Forex school, Forex technical analysis, forex, fundamental analysis, forex news, Forex Bonuses, forex signals, Forex Contest, Forex no deposit bonuses, Trading Binary Option
forex, forum, serbia, strategies, trade, binary, options, gold, only, three, languages, english, #russian, serbian, silever, cryptocurrency, discussions, about, trading


text:
Corey Haim Snubbed at Screen Actors Guild Awards
This year, the culprit is the Screen Actors Guild Awards, and the snubbed star is none other than Corey Haim, who, despite having several major films under his belt, was omitted from a montage clip that included fellow ex-child stars Gary Coleman and David Nelson, among others.
"We have become used to not being honored by our peers in the industry," Haim's 'Lost Boys' co-star and friend Corey Feldman tells PopEater upon learning of the snub. "I have faith that the Academy will make a wiser choice."
Haim, the former teen idol who rose to fame in 1980s classics 'The Lost Boys' and 'Lucas,' died March 10 at his mother's home in Burbank, Calif. An autopsy report labeled it a "natural death" and illegal drugs were not found in his system. He was 38.
All award ceremonies have their own policy on choosing who gets memorialized, and often it is tied to the date of their death. But the SAGs are known to be a little more loose in this regard and included Zelda Rubinstein, who died Jan. 27 of last year, and also Pete Postlethwaite, who died Jan. 3 of this year.
The Screen Actors Guild moved to explain the apparent slight on Monday, telling PopEater Haim was not included in the 'In Memoriam' package that aired because of time concerns.
"This year we prepared a longer version in hopes of being able to salute more actors and a shorter version if it was needed due to time," SAG Awards producer Kathy Connell explains. "Mr. Haim was in the longer version. As the show was running long, we were forced to chose the shorter package."
She added, "The Committee only wishes they had the time to salute everyone."
The big snub of 2010 was delivered to Farrah Fawcett at the Oscars, but as the Academy argued, the 'Charlie's Angels' star was primarily a TV star. Close friends and even her longtime parter Ryan O'Neal pointed out that she had many films, including 'The Apostle' and 'Extremities,' which gained her a Golden Globe nomination.
UPDATE 3:21 PM | Readers have flagged another snub. Actress and singer Dorothy Provine, who co-starred in films including 'It's a Mad, Mad, Mad, Mad World,' 'The Great Race' and 'That Darn Cat!', was also left off the montage. She died April 25 at 75.
- Filed under:
- Awards -
- Gut Reactions -
- Highbrow -
- Movie News -
- Celebrity Deaths -
- Videos
- Monday 31 JanuaryBy Sue M
That is awful.. Corey was more of an actor than Gary Coleman was. Ridiculous how they decide who is remembered. So Sad
- Monday 31 JanuaryBy Liz
True. I wasn't necessarily a Corey fan, but, i agree he was way better then Gary Coleman and aside from who we deem more talented, he was an actor who appeared in movies and he died and he certainly should not have been snubbed. Shame on the SAC it's things like this that start turning people against the award shows which will eventually cause their demise.
- Monday 31 JanuaryBy Ron in NY
To err is human, to moo, bovine.
- Monday 31 JanuaryBy CutieHigh Rank Vote downVote upReport this
.......John Denver was left off the year he died from the Oscars even though he made a few movies.
- Monday 31 JanuaryBy junior
That was an awards show? I thought it was a 2 hour promo for unions.
- Monday 31 JanuaryBy baobfng
This year, the culprit is the Screen Actors Guild Awards, and the snubbed star is none other than Corey Haim, who, despite having several major films under his belt, was omitted from a montage clip that included fellow ex-child stars Gary Coleman and David Nelson, among others.I love reading this , So does My boyfriend .he is almost 11year older than me .i met him via age'lessmate.c'om a nice place for seeking age le ss love.which gives you a chance to make your life better and open opportunities for you to meet the attractive young girls and treat you like a king. Maybe you wanna check it out or tell your friends..
- Monday 31 JanuaryBy Hmmm
What another hollywierd you would have us idolize! NOT - They may not have found drugs in his system, but it is drugs that killed him by killing his organs.
- Monday 31 JanuaryBy frankerin
And you know this HOW? Or are you one of these wanabee critics who live by contempt.
- Monday 31 JanuaryBy kbagenstose
Just because they honor someone who dies, that does not mean they are idolizing him, Hmmm! Yeah, he had problems, but he did some decent work, and he should be remembered for it. Stop being so ignorant!
- Monday 31 JanuaryBy tony
sad,he was alot better actor than gary coleman,oh well rip corey.
- Monday 31 JanuaryBy Bonbon
They do that every year with someone, just like they left Farrah out of the montage last year at the Academy Awards!
- Tuesday 01 FebruaryBy candy jones
corey was one of my favs for many years. many of the stars i never knew were gone.
- Monday 31 JanuaryBy Jennifer
It coouldn't be the date of death. It included David Nelson. He juist died in Jan 2011. Sad.
- Monday 31 JanuaryBy Polar Patrol
Corey may not have done any movies of note since the 80s, but with Silver Bullet, Lucas, and Lost Boys to his name - hell, even License to Drive wasn't bad - he should have been included.
- Monday 31 JanuaryBy Owen
Corey Haim hadn't been in a movie for a long time, so maybe that is the reason for the snub. He may have been a better actor than Gary Coleman, but Haim threw away his career (and his life) with drugs. He was given opportunities that few people are and he wasted them. Coleman was the victim of greedy parents and an unfortunate illness. Before any gets on me with the whole "addiction is a disease" nonsense, no one forced Haim to take the stuff. And although his death may have been ruled "natural causes," his body was probably so damaged from drug use that it had to have been a factor in his death.
- Monday 31 JanuaryBy scooterrr
It does NOT matter that he had a drug addiction. He was a former star who had died and he deserved to be in the Montage.
- Monday 31 JanuaryBy JenniferHigh Rank Vote downVote upReport this
Ok, if that whole hasn't made a movie in a long time holds up, why in the world was David Nelson added? He has NEVER made a movie. He was on a tv in the 60's with his family.
- Monday 31 JanuaryBy Zero
He might have been a cool guy but he died and left us, Major UNCOOL!
- Monday 31 JanuaryBy Jimm
Was Corey Haim a Republican?
- Monday 31 JanuaryBy david
Must have been
Jennifer Aniston
Is it Brad(ley) and Jen take 2? Jen was spotted out on the town with dreamboat ...
Paris Hilton
After Fairly Legal actress, Sarah Shahi, laid into Paris via Twitter for almost...
Kate Middleton
Kate Middleton is officially a princess. She walked the aisle in an Alexander...
Denise Richards
According to Denise, she's not sure that her estranged ex is completely sober....
Popeater Hot Topics
- Craig Morgan on MSNBC guest's criticism of country music: Comment was 'ignorant'
- Lena Dunham called anti-Semitic for article titled 'Dog or Jewish Boyfriend?'
- FOX411's pic of the day
- Patrick Stewart Snorts Coke in First Trailer for Starz's 'Blunt Talk' (Video)
- ADL Slams Lena Dunham for "Dog or Jewish Boyfriend" New Yorker Quiz
- NBC Orders Ellen DeGeneres-Produced Docuseries 'First Dates'
- 'Home' Review: 5 Things Every Parent Needs to Know
- Jake Gyllenhaal's Transformation for 'Southpaw' Is Crazy (VIDEO)
- 9 Reasons Why the 'X-Files' Revival Matters
Sites We Love
- Craig Morgan on MSNBC guest's criticism of country music: Comment was 'ignorant'
- Lena Dunham called anti-Semitic for article titled 'Dog or Jewish Boyfriend?'
- More From Foxnews.com
- Shailene Woodley Likes to Eat What!?
- Prince William: Having a Second Child Is a 'Game-Changer'
- More From PEOPLE.com
- Yemenis Vine, Instagram, And Livetweet Two Days Of Bombardment
- 37 Things You Learn From Working In A Comic Shop
- We Asked People What They Really Thought About Zayn Leaving One Direction
- More From Buzzfeed
- Zayn Malik Breaks Silence on One Direction Exit
- Molly Sims Gives Birth to Baby Girl
- More From stylelist.com